Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Improvement in cognitive dysfunction with IV albumin in patients with cirrhosis
with prior HE and MHE lasts for several weeks after albumin infusion has ended, and is due to
persistent improvement in inflammatory markers, endothelial dysfunction, albumin function and
gut microbial changes.
This will be a single-arm, single-blind sequential trial of IV 25% albumin and IV saline over
8 weeks with biological sampling and cognitive and health related quality of life (HRQOL)
testing with each subject acting as their own control.
Phase:
Phase 2
Details
Lead Sponsor:
Hunter Holmes Mcguire Veteran Affairs Medical Center